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Human fungal infections represent a therapeutic challenge. Although effective strategies for treatment are available, resistance is
spreading, andmany therapies have unacceptable side effects. A clear need for novel antifungal targets andmolecules is thus emerging.
Here, we present the identiﬁcation and characterization of the plant-derived diyne-furan fatty acid EV-086 as a novel antifungal com-
pound. EV-086 has potent and broad-spectrum activity in vitro against Candida, Aspergillus, and Trichophyton spp., whereas activi-
ties against bacteria and human cell lines are very low. Chemical-genetic proﬁling of Saccharomyces cerevisiae deletion mutants
identiﬁed lipid metabolic processes and organelle organization and biogenesis as targets of EV-086. Pathway modeling suggested
that EV-086 inhibits delta-9 fatty acid desaturation, an essential process in S. cerevisiae, depending on the delta-9 fatty acid de-
saturase OLE1. Delta-9 unsaturated fatty acids—but not saturated fatty acids—antagonized the EV-086-mediated growth inhi-
bition, and transcription of the OLE1 gene was strongly upregulated in the presence of EV-086. EV-086 increased the ratio of
saturated to unsaturated free fatty acids and phosphatidylethanolamine fatty acyl chains, respectively. Furthermore, EV-086 was
rapidly taken up into the lipid fraction of the cell and incorporated into phospholipids. Together, these ﬁndings demonstrate
that EV-086 is an inhibitor of delta-9 fatty acid desaturation and that the mechanism of inhibition might involve an EV-086–
phospholipid. Finally, EV-086 showed efﬁcacy in a guinea pig skin dermatophytosis model of topical Trichophyton infection,
which demonstrates that delta-9 fatty acid desaturation is a valid antifungal target, at least for dermatophytoses.
Healthy individuals are remarkably resistant to fungal infec-tions. However, predisposing factors, such as age, immuno-
suppression, and underlying disease, weaken the immune system
and render the host susceptible to fungal infections. Humid con-
ditions and occlusive clothing further favor fungal growth on the
skin. Fungal disease is therefore widespread and manifests in a
spectrum from relatively mild dermatophytoses to serious sys-
temic infections (1).
Chemotherapy has proven to be a highly effective strategy for
the treatment of fungal infections. The majority of agents applied
for the treatment of dermatophytoses are from the allylamine and
azole family. Triazoles, polyenes, and echinocandins are currently
the main classes used to treat systemic fungal infections. Both the
allylamines and the azoles inhibit the biosynthesis of ergosterol, an
essential membrane component crucial for the physico-chemical
properties of themembrane. Polyenes do not target the ergosterol
biosynthetic pathway but directly bind to membrane sterols. The
echinocandins target beta-glucan synthesis, which is essential for
cell wall biosynthesis (2–4).
Even though current chemotherapeutic strategies for the treat-
ment of human fungal infections are effective, the widespread use
of antifungal compounds has generated resistance, and many
therapies are now losing efﬁcacy (5, 6). A clear need for novel
antifungal targets and molecules is therefore emerging. Ideally,
antimicrobial molecules act multifactorially, inhibiting different
essential processes. This ensures fast and efﬁcient clearance of the
pathogen while minimizing the risk of resistance development.
Remarkably, the azoles, polyenes, and allylamines all target either
ergosterol directly or its biosynthesis, which eventually impairs
membrane-associated processes and adaptation to the environ-
ment. Membrane components such as ergosterol are therefore
attractive antifungal targets (7).
Here, we present the identiﬁcation of the plant derived diyne-
furan fatty acid EV-086 as a novel and speciﬁc antifungal compound.
Chemical-genetic proﬁling and transcript analysis revealed that EV-
086 targets delta-9 fatty acid desaturation, an essentialmetabolic step
in the biosynthesis of unsaturated fatty acids. EV-086 thus interferes
with the biosynthesis of membrane components similar as do the
azoles, polyenes, and allylamines, but via a differentmechanism. The
efﬁcacy of EV-086was validated in vivo in a guinea pig skin dermato-
phytosis model of fungal infection.
MATERIALS AND METHODS
Isolation of metabolites with antifungal activity from plant cell cul-
tures.A library of puriﬁed plantmetabolites was screened for compounds
with antifungal activity. The library was prepared from plant cell cultures
as described previously (8, 9). Brieﬂy, callus cultures were established on
agar and then grown in suspension culture. The suspension cultures were
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subjected to a series of treatments to activate secondary metabolic path-
ways. About 40,000 different metabolites were puriﬁed from more than
2,000 plant cell cultures by using preparative high-performance liquid
chromatography. The isolated compounds were then screened for anti-
fungal activity by broth microdilution at ﬁnal concentrations of 200, 100,
50, 10, and 1 g/ml as described previously (10). In each well of a 96-well
plate, 5 l of test sample in dimethyl sulfoxide (DMSO) was combined
with 95 l Candida albicans SC5314 (11) suspension in RPMI medium
(10.4 g/liter; R6504 buffered at pH 7 with 0.165 M morpholinepropane-
sulfonic acid; Sigma), resulting in a ﬁnal suspension of 5  103 cells/ml.
The plates were shaken and incubated at 35°C for 24 h. A 25-l aliquot of
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxa-
nilide salt (XTT) stock solution was added to each well, and the plate was
incubated on a shaker for another 2 h at 35°C. Absorption was measured
at 470 nm in a spectrometer, and the 50% inhibitory concentation (IC50)
was determined by using nonlinear least square ﬁtting.
A metabolite with an IC50 below 1 g/ml was identiﬁed from a plant
cell culture of Anarrhinum bellidifolium and designated EV-086. Detailed
culture conditions and extraction procedures for the isolation of EV-086
were as follows. Plant seeds were sterilized, and seeds were placed on seed
germination medium (modiﬁed after Gamborg’s B5 recipe [12]; 1% su-
crose, no hormones, and 10 mg/liter propiconazole). Seedlings were
chopped into small pieces and placed on solidiﬁed callus induction me-
dium (modiﬁed after Gamborg’s B5 recipe, containing 1 mg/liter 2,4-
dichlorophenoxyacetic acid, 0.1 mg/liter kinetin, 100 ml/liter coconut
water, and 2% sucrose). Portions of seedling explant and callus were
placed in suspension medium (modiﬁed after Gamborg’s B5 recipe con-
taining 1 mg/liter 2,4-dichlorophenoxyacetic acid, 0.1 mg/liter kinetin,
100 ml/liter coconut water, and 3% sucrose) and replenished at 14-day
intervals. Conical ﬂasks containing 750 ml of suspension medium were
inoculated with 250 ml of 14-day-old suspension culture. After 7 days of
growth, ﬁlter-sterilized methyl jasmonate (250 M, ﬁnal concentration)
and an autoclaved C. albicans preparation (50 mg/liter, ﬁnal concentra-
tion) were added for defense system induction. Cell cultures were incu-
bated for 6 days, harvested by vacuumﬁltration, and freeze-dried. Freeze-
dried cell biomass was extracted withmethylene chloride-methanol (1:1).
The dried extract was absorbed and fractionated on a Diaion HP-20 col-
umn (catalog number 13606; inner diameter of 2.5 cm, 25 cm deep;
Sigma) and eluted with H2O, 20% methanol in H2O, methanol, and ace-
tone. The structure of EV-086 was elucidated by mass spectrometry and
nuclear magnetic resonance.
Susceptibility testing of yeasts and ﬁlamentous fungi. MICs were
determined by brothmicrodilution according to the Clinical and Labora-
tory Standards Institute (CLSI) reference methods for antifungal suscep-
tibility testing of yeasts and ﬁlamentous fungi (13, 14). Brieﬂy, EV-086
was dissolved in ethanol, and serial 2-fold dilutions of 100 concentrated
compoundwere further diluted 1/50 in RPMImedium.Aliquots of 100l
of cell or conidia suspensions (2,000 cells or conidia/ml) were added to
96-well plates, and 100l of test compound diluted in RPMImediumwas
added. The endpoint was complete growth inhibition (optically clear),
determined by visual inspection of growth wells. Saccharomyces cerevisiae
strains were tested in synthetic complete (SC) medium (15). Checker-
board assays combining test compounds with fatty acids were set up ac-
cordingly. EV-086 and fatty acids were prepared as 4-fold dilutions in
RPMImedium. Fifty-microliter aliquots were combined in 96-well plates
and inoculated with 100 l cell or conidia suspension.
Viability of C. albicans in response to EV-086 was determined in a
time-kill kinetic analysis.C. albicansATCC 24433 was inoculated at 1,000
cells/ml in RPMI medium. Viability of the cells was analyzed before com-
pound addition and after 1 h, 2 h, 4 h, 8 h, 24 h, and 48 h with compound
by plating 100 l of culture on potato dextrose agar plates (PDA; Difco
catalog number 213300). Dilutions in saline were made when cultures
reached higher densities. Plates were incubated for 2 days, and culture cell
densities were calculated based on the CFU. A carryover effect was negli-
gible up to 500 ng/ml EV-086 in culture.
Susceptibility testing of bacteria.TheMICswere determined accord-
ing to the CLSI reference method for dilution antimicrobial susceptibility
tests for bacteria (16). Brieﬂy, EV-086 was dissolved in ethanol, and serial
2-fold dilutions of 100 concentrated compounds were further diluted
1/50 inMueller-Hinton broth. Cell suspension aliquots (100l; 106 cells/
ml)were added to 96-well plates, and 100l of diluted test compoundwas
added. The endpoint was complete growth inhibition (optically clear),
determined by visual inspection of growth wells.
Mammalian cytotoxicity assay. Cell viability was tested with a color-
imetric assay that measured metabolic activity (17). Brieﬂy, HepG2 and
HeLa cells were grown at 37°C in 95% oxygen and 5% CO2 in Dulbecco’s
modiﬁed Eagle medium (Sigma) supplemented with 10% heat-inacti-
vated fetal calf serum, 2 mM L-glutamine, 50 U/ml penicillin, and 50
g/ml streptomycin (Pen/Strep). Cells were seeded into 96-well plates in
mediumwithout Pen/Strep at a density of 2 104 (HepG2) or 104 (HeLa)
cells perwell and incubated for 1 daywithout test compound. Serial 3-fold
dilutions of EV-086 were prepared as DMSO stock solutions, diluted in
mediumwithout Pen/Strep, and added to the cell layers (1%DMSO, ﬁnal
concentration). Cells were incubated for 2 days with compound. Fifty
microliters of XTT stock solution was added to each well. After 4 h, ab-
sorption at 470 nm was determined as the measure of viability. Absorp-
tion of control wells was subtracted from all measurements. Nonlinear
least square ﬁtting was applied to determine the 50% cytotoxic concen-
tration.
Chemical-genetic proﬁling of Saccharomyces cerevisiae against EV-
086. A collection of 4,917 homozygous diploid BY4743-derived S. cerevi-
siae knockout strains served as the screening library (catalog number
YSC1056; Thermo Fisher Scientiﬁc, OpenBiosystems). The library strains
were cultured in YPD medium (1% Bacto yeast extract, 2% Bacto pep-
tone, 2% dextrose) in a 96-well format, and aliquots were spotted onto
YPD agar (2% agar) containing 0, 0.5, 2, or 8 g/ml EV-086 by using a
96-pin replicator. Susceptibility to EV-086 was determined after 2 days by
visual inspection of the colony diameters in comparison to those of the
parent strain, BY4743 (18). Primary hit strains were recultured and veri-
ﬁed in a secondary drop spot assay. The biological processes associated
with the deleted genes were determined for the identiﬁed strains (19, 20).
A hypergeometric distribution was calculated to determine signiﬁcantly
overrepresented biological processes in the sample compared to the pop-
ulation, and a Bonferroni correction was applied to correct for the family-
wise error rate (21).
Transcript proﬁling of the OLE1 gene. S. cerevisiae BY4743 (18) was
cultured in SC medium (15). RNA was isolated by glass bead extraction
from2 107 yeast cells (RNeasyminikit; Qiagen). cDNAwas prepared by
two-step reverse transcription-PCR (RT-PCR; QuantiTect reverse tran-
scription kit; Qiagen). cDNA levels were determined quantitatively on a
Rotor-GeneQ 2plex platform (Rotor-Gene SYBR green PCRkit; Qiagen).
Reactions were performed in triplicate, and the normalized relative ex-
pression was calculated using the CT method (22). The alpha-tubulin
gene (TUB1) served for normalization of cDNA. Oligonucleotides 5=-TG
GGACAAACAAACCTT-3= and 5=-CACCACCTGGATGTTCAGAG-3=
were used for ampliﬁcation of the S. cerevisiae OLE1 gene, and oligonu-
cleotides 5=-CCAGATGGTCAAGTGTGATCC-3= and 5=-CAACCAATT
GGACGGTCTTC-3= were used for the ampliﬁcation of the TUB1 gene
(23–25). One-way analysis of variance (ANOVA) with Dunnett’s post hoc
test was performed using the Prism software (version 5.00 for Windows;
GraphPad Software, San Diego CA).
S. cerevisiae lipid extraction and analysis.To analyze relative levels of
unsaturated and saturated free fatty acids and molecular species of phos-
pholipids, lipids were extracted and analyzed as described previously (26).
Brieﬂy, cultured S. cerevisiae cells were collected by centrifugation, resus-
pended in 150 mM ammonium bicarbonate (pH 8), and disrupted with
0.5-mmzirconia beads (catalog numberD1032-05; Benchmark Scientiﬁc,
Edison, NJ). Disrupted yeast cells were extracted with chlorophorm-
methanol (17:1, vol/vol) and analyzed bymass spectrometry on a Brucker
Esquire HCT ion trap mass spectrometer (electrospray ionization) with a
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ﬂow rate of 250l/h and a capillary tension of250V. Ion fragmentation
was induced with argon as the collision gas at a pressure of 800 Pa. To
compare uptake and incorporation of EV-086 to those of palmitic acid,
cells were cultivated in the presence of 5 g/ml of either [14C]EV-086 or
[14C]palmitic acid, both with a speciﬁc activity of 0.08 Ci/ml. At each
time point, 10 optical density (OD) units of cells were withdrawn. Lipids
were extracted with chlorophorm-methanol (1:1) from the cell pellet and
the culture supernatant and subjected to scintillation counting. Aliquots
were dried and separated by thin-layer chromatography (TLC) on silica
gel 60 plates (Merck, Darmstadt, Germany) by using the solvents CHCl-
methanol-acetic acid (65/25/8, vol/vol/vol). The TLC was dried and ex-
posed to a phosphorimager screen, and the screen was developed using a
Typhoon FLA 9500 imager (GE Healthcare, GmbH, Europe).
Guinea pig skin dermatophytosis model of infection. The efﬁcacy of
EV-086 was determined in guinea pig model of Trichophyton menagro-
phytes skin dermatophytosis as previously described (27). Brieﬂy, T. men-
tagrophytesATCC 24953 was prepared as a suspension of 2 108 conidia/
ml. Male albino guinea pigs (Harlan-Sprague-Dawley, San Diego, CA)
were randomly assigned to ﬁve different experimental groups with 10
animals in each group. Square areas (3 cmby 3 cm) of skinwere shaved on
the animals’ backs and abraded using sterile emery paper. A total of 1
107 T. mentagrophytes conidia were applied. The ﬁve experimental groups
were treated as follows: untreated control, vehicle control (Captex 350;
Abitec, Columbus, OH), 0.1% EV-086 (in Captex 350), 1% EV-086 (in
Captex 350), or 1% terbinaﬁne (Lamisil commercial formulation; No-
vartis) as the positive control. For mycological evaluations of the test
compounds, hair samples were removed with a sterile forceps from the
infected areas. Ten hair samples from each animal were inoculated, and
the mycological efﬁcacy was expressed as the percentage of mycologically
positive hairs compared to the untreated control. Clinical assessments of
local changes of the infected skin were scored from 0 (no ﬁndings) to 5
(extensive damage), and the clinical efﬁcacy was expressed as a percentage
relative to the result for the untreated control group. One-way ANOVA
with Dunnett’s post hoc test was performed using Prism software (version
5.00 for Windows; GraphPad Software, San Diego CA). All procedures in
the protocol were in compliance with the Animal Welfare Act, the NRC
Guide for the Care and Use of Laboratory Animals (56), and the Ofﬁce of
Laboratory Animal Welfare. Guinea pigs were used upon review and ap-
proval of an addendum to our existing protocol by the Institutional Ani-
mal Care and Use Committee (IACUC).
RESULTS
A plant cell culture screen for natural antifungal compounds
identiﬁed the diyne-furan fatty acid EV-086. In our search for
novel natural compounds with antifungal activity, a library of pu-
riﬁed plant cell culture metabolites was screened for compounds
with activity against C. albicans. More than 40,000 puriﬁed com-
pounds were tested for antifungal activity in an XTT-based broth
microdilution assay. This screen identiﬁed a metabolite from An-
arrhinum bellidifolium with a MIC of 2.5 ng/ml against the C.
albicans strain ATCC 24433. The compound had a Mw of 284.35
andwas designated EV-086. Spectroscopic analyses identiﬁed EV-
086 as a diyne-furan substituted (Z)-9 unsaturated fatty acid
[chemical name, (Z)-14-(furan-2-yl)tetradeca-9-en-11,13-di-
ynoic acid] (Fig. 1a). Chemically synthesized EV-086 (as the po-
tassium salt, Mw 322.44) conﬁrmed the activity of the original
molecule and was used for all further studies unless otherwise
indicated. The thermodynamic aqueous solubility determined for
EV-086 (potassium salt) was above 96.5 mg/ml (28). The calcu-
lated average logP of EV-086 was 4.98 0.92 (29).
EV-086 is a selective, broad-spectrum antifungal compound
with potent activity in vitro.TheMIC of EV-086 was determined
against a panel of reference yeasts and ﬁlamentous fungi relevant
for systemic and topical human fungal infections by using CLSI
referencemethods (13, 14). Fluconazole, amphotericin B, and ter-
binaﬁne served as comparators (Table 1). EV-086 was highly po-
tent against Candida spp., with MICs of 2.5 ng/ml for C. albicans
and 80 ng/ml for C. glabrata. Similar high potency was observed
for Trichophyton spp., with an MIC of 8 ng/ml for T. mentagro-
phytes. EV-086was also active againstAspergillus fumigatus, with a
MICof 640 ng/ml. EV-086 showed only low activities againstCan-
dida parapsilosis, Aspergillus ﬂavus, and Aspergillus niger. There
was nomajor difference in activity between the potassium salt and
the free acid of EV-086 as determined for ﬁve different Candida
species. The MIC of EV-086 against the diploid S. cerevisiae labo-
ratory strain BY4743 was 64 ng/ml, and it was 16 ng/ml for the
haploid BY4742 and BY4741 strains.
The effect of EV-086 on the viability ofC. albicansATCC24433
was investigated in a time-kill kinetic assay. Cell suspensions were
incubated in shaking ﬂasks, and CFUs were determined during a
48-h incubation period with agar plating (Fig. 2). The reference
MICs against the C. albicans assay strain ATCC 24433 were 2.5
ng/ml for EV-086, 400 ng/ml for ﬂuconazole, and 1000 ng/ml for
amphotericin B. A reduction of CFUswas observed after4 h and
at5 ng/ml EV-086. After an incubation period of 24 h, EV-086
reduced the CFUs by10-fold and100-fold at 20 and 320 ng/
ml, respectively. Fluconazole at 16 g/ml showed an increase in
the CFUs of137-fold after 24 h, while the CFUs for amphoter-
icin B were below the limit of detection at this concentration.
The activity of EV-086 was selective against fungi. Only very
high concentrations inhibited the growth of mammalian cells or
bacteria. The cytotoxic concentration of EV-086 againstHeLa and
HepG2 cells was 40 g/ml. The MICs against Staphylococcus
aureus,Enterococcus faecalis, andEscherichia coliwere 50, 12.5, and
200 g/ml, respectively.
In summary, EV-086 showed a broad-spectrum activity that
was selective against fungi. EV-086 was equally potent or more
potent compared to the reference compounds ﬂuconazole, am-
photericin B, and terbinaﬁne for most of the tested fungi, and
EV-086 reduced viability of the cells in the time-kill kinetic assay.
EvaluationofEV-086analogues revealedanarrowstructure-
activity relationship. A primary structure-activity relationship
(SAR) was determined to characterize the functional groups in
EV-086. Fifteen analogues of EV-086 were synthesized, and the
activities were determined as a measure of C. albicans in vitro
susceptibility (Fig. 1).
Modiﬁcations of the carboxylic acid group were not tolerated.
EV-086–tetrazole, which mimics the electron distribution of a
carboxylic acid, EV-086–amide, –alcohol, –methoxy, or –ethyl-
ester were inactive, with100-fold decreased potency compared
to the parent compound EV-086 (Fig. 1a to f). A trans conforma-
tion at carbon C-9 abolished the activity, whereas a saturation of
the C-9–C-10 bond was tolerated, resulting in a MIC of 20 ng/ml
for the EV-086–9–saturated analogue (Fig. 1g and h). Alkyl chain
length modiﬁcations at the carboxylic acid terminus were not tol-
erated. Similarly, the removal of one triple bond inactivated the
molecule (Fig. 1i to k). Mimicking the diyne-furan moiety with a
benzofuran also inactivated the molecule (Fig. 1l). Certain modi-
ﬁcations in the furan ring were tolerated. Oxazole analogues with
a nitrogen substitution at the C-18 or C-17 carbons resulted in
MICs of 20 ng/ml, whereas a C-16 substitution or the 18-methyl-
furan modiﬁcations were inactive (Fig. 1m to p).
Together, these data suggest a narrow structure-activity rela-
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tionship for the EV-086 class of molecules. The distance between
carbon atoms C-1 and C-9 cannot be changed. The C-9–C-10
carbonsmust not be in the trans conﬁguration, whereas the cis and
saturated forms are active. A minor degree of freedom was found
for the furan part of the molecule, whereas the diyne moiety did
not accept changes.
Chemical-genetic proﬁling of yeast identiﬁed lipid metabo-
lismandorganelle organization andbiogenesis as targets of EV-
086. Chemical-genetic proﬁling of S. cerevisiae knockout mutants
was carried out to identify the target pathway of EV-086 (Fig. 3a).
Brieﬂy, 4,917 homozygous diploid S. cerevisiae strains, each with
one deﬁned open reading frame (ORF) deleted (30), were individ-
ually cultured and replica plated on agar plates containing a per-
missive (0.5 g/ml), semipermissive (2 g/ml), or restrictive (8
g/ml) concentration of EV-086. Plates were incubated and col-
ony growth recorded. Strains hypersensitive to EV-086 were ver-
iﬁed in a secondary drop spot assay (Fig. 3b and c). This revealed
44 genes that rendered S. cerevisiae hypersensitive to EV-086when
deleted. The S. cerevisiaeGO-Slim vocabulary was used tomap the
identiﬁed genes to higher-level biological processes (Table 2) (19,
20). The 44 identiﬁed genes mapped to 24 out of 39 available
biological processes. A signiﬁcant overrepresentation was deter-
mined for lipid metabolic process (P  0.004) and organelle or-
ganization and biogenesis (P 0.04).
Assembly of a putative pathway as the target of EV-086.
Based on the identiﬁed genes, associated biological processes, and
data in the literature, we assembled putative pathways as targets of
EV-086. Most promising was a pathway controlling delta-9 fatty
acid desaturation. In this pathway, the genes GET1, GET2, GET3,
SSM4, UBX2, UBC7, and MGA2, which were identiﬁed in the
chemical-genetic proﬁling, are included (Fig. 4).
As reported in the literature, the GET complex, consisting of
Get1p,Get2p, andGet3p,mediates insertion of tail-anchored pro-
teins into the endoplasmic reticulum (ER) membrane (31). Fur-
thermore, the transcription factor Mga2p has been reported to
localize to the ER membrane (32). Sequence analysis predicts a
C-terminal transmembrane domain in Mga2p (33), and multiple
genetic interactions between MGA2 and GET1, GET2, or GET3
have been reported (34–37). We therefore hypothesized that the
GET complex alsomediates insertion ofMga2p into the ERmem-
brane. It has further been reported that the 120-kDa ER-associ-
ated form of Mga2p is proteolytically processed to a soluble 90-
FIG 1 Structures and activities of EV-086 and analogues. (a) EV-086 as the free acid. Numbering of the carbon atoms starts at the carboxylic acid carbon, with
1, and ends in the furan ring, with 18. The position of the [14C]carbon in the labeled EV-086 is indicated with an asterisk at position 14. (b to p) Analogues of
EV-086. Activities are given as MICs against the C. albicans ATCC 24433 reference strain.
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kDa form in a Cdc48p-dependent ER-associated protein
degradation (ERAD) process (32). Ubx2p is a bridging factor that
links Cdc48p to Ssm4p, Ssm4p is a membrane-associated ubiqui-
tin protein ligase, and Ubc7p is a ubiquitin-conjugating enzyme
(38, 39). We therefore hypothesized that Ubx2p, Ssm4p, and
Ubc7p are involved in an ERAD-dependent proteolysis ofMga2p.
Indeed, bothUBX2 and SSM4 genetically interact withMGA2 (24,
44), and Spt23p, a functional homologue ofMga2p in S. cerevisiae,
has been identiﬁed as a Ubx2p substrate (40). Finally, it has been
well described that the soluble 90-kDa Mga2p shuttles to the nu-
cleus, where it induces transcription of the OLE1 gene, which en-
codes the delta-9 fatty acid desaturase Ole1p, an essential gene in
S. cerevisiae (41). Ole1p subsequently converts saturated fatty
acyl-coenzyme A (CoA) substrates to monounsaturated fatty acid
species by an oxygen-dependent mechanism (32).
In summary, the identiﬁed genes from the chemical-genetic
proﬁling in the context of the data in the literature allowed us to
assemble a putative pathway as the possible target of EV-086.
From this work, we propose delta-9 fatty acid desaturation as the
target of EV-086 and an involvement of the GET complex and
ERAD in Mga2p-dependent transcriptional activation of OLE1.
EV-086 targets delta-9 fatty acid desaturation. In order to test
if EV-086 targets delta-9 fatty acid desaturation, we investigated
whether delta-9 unsaturated fatty acids antagonized the growth-
inhibitory effect of EV-086 in S. cerevisiae and C. albicans (Fig. 5).
S. cerevisiae was grown in the presence of EV-086 supple-
mented with oleic acid or stearic acid. Indeed, oleic acid but not
stearic acid antagonized EV-086 in wild-type S. cerevisiae. In the
TABLE 1 MICs of EV-086 and comparators against different fungal reference strains and S. cerevisiae laboratory strains
Species and strain(s)
Incubation temp
and time
MIC (ng/ml)
EV-086
potassium salt EV-086 free acid FLC AMB TRB
C. albicans
ATCC 24433 35°C, 2 days 2.5 2.5 400 1,000 —
SC5314 35°C, 2 days 2.5 — — — —
C. glabrata ATCC 90030 35°C, 2 days 80 40 200 1,000 —
C. krusei ATCC 6258 35°C, 2 days 40 40 1,600 2,000 —
C. tropicalis ATCC 750 35°C, 2 days 5 5 200 2,000 —
C. parapsilosis ATCC 22019 35°C, 2 days 10,240 10,240 50 1,000 —
A. fumigatus ATCC MYA-3626 35°C, 2 days 640 — — 1,000 —
A. ﬂavus ATCC MYA-3631 35°C, 2 days 5,120 — — 1,000 —
A. niger ATCC 10578 35°C, 2 days 5,120 — — 1,000 —
A. terreus ATCC MYA-3633 35°C, 2 days 80 — — —
T. rubrum ATCC 4438 35°C, 4 days 4 — — 512
T. mentagrophytes strains
ATCC 4439 35°C, 4 days 8 — — 8
ATCC 24953 35°C, 4 days 4 — — —
S. cerevisiae strains
BY 4741 30°C, 1 day 16 — — —
BY 4742 30°C, 1 day 16 — — —
BY 4743 30°C, 1 day 64 — — —
a FLC, ﬂuconazole; AMB, amphotericin B; TRB, terbinaﬁne; —, not determined.
FIG 2 Time-kill kinetics of EV-086 and comparators against C. albicans
ATCC 24433.C. albicans growth is given as the log CFU at time t (ct) versus the
CFU at time zero (c0). Compound concentrations tested in cultures and cor-
responding symbols are shown in the key.
FIG 3 Chemical-genetic proﬁling of the S. cerevisiae knockout mutant collec-
tion. The concentrations of EV-086 in the YPD agar test plates are indicated,
with 0.5 g/ml as permissive, 2 g/ml as semipermissive, and 8 g/ml as
restrictive. (a) Example frame of the primary screening, showing 9 different
knockout strains. The white circle highlights a hypersensitive deletion strain
(mga2 deletion). (b and c) Hypersensitive deletion strain mga2 (b) and the
wild-type strain (BY4743) (c) in secondary drop spot assays. The frames in
panels b and c show the 3-step 10-fold serial dilution of cell suspensions spot-
ted on agar plates. Growth of the hypersensitive deletion strain (b) was inhib-
ited at 0.5 g/ml EV-086, whereas the wild-type strain (c) showed about 50%
growth at 2 g/ml.
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TABLE 2 Deleted genes and associated biological processes of the S. cerevisiae knockout mutants hypersensitive to EV-086
a Signiﬁcantly overrepresented biological process (P 0.05). Genes in the category “biological process unknown” were signiﬁcantly underrepresented.
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presence of 28 g/ml oleic acid, the inhibitory effect of up to 8
g/ml EV-086 was antagonized. Further, oleic acid comple-
mented the EV-086-dependent growth defect of get1, ubx2, and
mga2 deletion mutants, representing the GET complex, ERAD
function, and OLE1 transcription, respectively. The growth de-
fects in these mutants, however, were not fully complemented,
most likely due to other functions of these genes (Fig. 5a). We
further demonstrated an antagonism between EV-086 and oleic
acid for C. albicans and T. mentagrophytes (Fig. 5b and data not
shown). The oleic acid antagonism was also conﬁrmed for the
analogues EV-086–9-saturated, –18-oxazole, and –17-oxazole in
C. albicans (Fig. 1 and data not shown).
FIG 4 Putative signaling pathway controlling delta-9 fatty acid desaturase activity. (a) The GET complex directs the putative tail-anchored protein Mga2 to the
ER membrane. (b) Membrane-bound Mga2p is proteolytically cleaved in an ERAD-dependent process to release the soluble 90-kDa form from its 120-kDa
membrane-bound form. (c) The soluble 90-kDa form of Mga2p is shuttled to the nucleus, where it activates transcription of the OLE1 gene. (d) Transcribed
OLE1 is translated intoOle1p, which is targeted to the ERmembrane. (e) Ole1p catalyzes delta-9 fatty acid desaturation. n	 number of CH2 units; 5 for palmitic
and palmitoleic acid; 7 for stearic and oleic acid.
FIG 5 Antagonism between EV-086 and delta-9 unsaturated fatty acids. (a) Wild-type (wt) S. cerevisiae BY4743 and get1, ubx2, and mga2 deletion strains
(BY4743 background) were prepared as suspensions and spotted onto YPD agar plates containing different concentrations of EV-086. Oleic acid and stearic acid
were added to agar plates at the indicated concentrations. (b) Serial dilutions of EV-086 were combined with oleic acid, linoleic acid, or stearic acid in a
checkerboard setup and inoculated with C. albicans ATCC 24433. Growth was recorded by visual inspection according to the following scale: 0, optically clear;
1, slightly hazy; 2, prominent decrease (50%) in visible growth; 3, slight reduction in visible growth; 4, no reduction in visible growth.
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Together, these data showed that EV-086 targets delta-9 fatty
acid desaturation and that the target is conserved at least in S.
cerevisiae, C. albicans, and T. mentagrophytes.
EV-086 induces a transcriptional upregulation of OLE1.
Based on our proposed pathway, we wanted to investigate at
which level EV-086 targets delta-9 fatty acid desaturation: either at
the Mga2p-dependent transcriptional control of OLE1 or post-
transcriptionally. We therefore determined the expression of the
OLE1 gene in EV-086-treated S. cerevisiae cells by using quantita-
tive PCR.
S. cerevisiae BY4743 was cultured with EV-086 at concentra-
tions of 1 and 10g/ml. Culture samples were taken at 10, 60, 120,
and 240 min, and the relative transcription of OLE1 was deter-
mined as the fold change compared to the untreated control at 10
min (Fig. 6). A 10- to 20-fold increase in expression was observed
between 60 and 240minof incubationwith 10g/ml EV-086 (P
0.01), whereas the expression of OLE1 in the untreated control
remained unchanged during the incubation period. At 1 g/ml
EV-086, the increase was around 5-fold (P  0.05). Since oleic
acid antagonized the growth inhibition of EV-086, the expression
ofOLE1was further examined in the presence of 10g/ml EV-086
plus 10g/ml oleic acid.Under these conditions, the expression of
OLE1 was reduced to the level of oleic acid alone. In analogy, the
expression of OLE1 was also determined in C. albicans ATCC
24433. After 240 min, the expression increased about 5-fold com-
pared to the untreated control (data not shown).
These ﬁndings suggest that EV-086 does not target delta-9 fatty
acid desaturation at theMga2p-dependent transcriptional control
ofOLE1 level but rather posttranscriptionally. This mechanism of
inhibition is conserved between S. cerevisiae and C. albicans, and
homologues of both MGA2 and OLE1 have been identiﬁed in C.
albicans (42, 43).
EV-086 increases the ratio of saturated to unsaturated fatty
acids. Inhibition of delta-9 fatty acid desaturation is expected to
change the saturation proﬁle of free fatty acids and phospholipid
fatty acyl chains. In order to verify EV-086’s inhibitory activity
against delta-9 fatty acid desaturation, the saturation degrees of
free fatty acids and phosphatidylethanolamine (PE) fatty acyl
chains were determined in S. cerevisiae.
Haploid wild-type S. cerevisiae BY4742 was cultured in SCme-
diumwith 10g/ml EV-086, and culture samples were taken after
240min of incubation. Lipids were extracted, and relative levels of
free C16 and C18 fatty acids were analyzed by mass spectrometry
(Fig. 7a). For both C16 and C18 free fatty acids, EV-086 increased
the ratio of saturated to unsaturated fatty acid by about 2.5- to
3-fold compared to the untreated control: the ratios of 16:0/16:1
fatty acids were 0.5 in untreated cells and 1.7 in drug-treated cells,
and the ratios of 18:0/18:1 fatty acids were 1.8 in untreated cells
and 4.6 in drug-treated cells (P 0.001). Accordingly, the satura-
tion proﬁle of PE fatty acyl chains was analyzed (Fig. 7b). Simi-
larly, EV-086 increased the ratio of saturated to unsaturated fatty
acid acyl chains by 3- to 6-fold for PE(32:1/32:2), PE(34:1/34:2),
and PE(36:1/36:2). Further, PE was shifted toward species with
elevated levels of shorter fatty acyl chain substitutions.
These profound increases in the ratio of free saturated to un-
saturated fatty acids and PE fatty acyl chains corroborate delta-9
fatty acid desaturation as the target of EV-086. Further, the shift
toward PE species with elevated levels of shorter fatty acyl chains
likely reﬂects an adaptive response to the inhibition of delta-9 fatty
acid desaturation.
Radiolabeled EV-086 is incorporated into phospholipids in
S. cerevisiae. Exogenous fatty acids added to the growth medium
are rapidly incorporated into phospholipids in S. cerevisiae (44).
The structural conservation between EV-086 and common fatty
FIG 6 Expression of OLE1 and dependence on EV-086. Diploid S. cerevisiae
BY4743 cells were inoculated in SC medium at a density of 5  106 cells/ml.
Cultures were supplemented with ethanol (vehicle), 1 g/ml EV-086, 10
g/ml EV-086, 10 g/ml oleic acid (OA), or 10 g/ml EV-086 plus 10 g/ml
OA. Culture samples were taken at 10, 60, 120, and 240 min after compound
addition. The expression of OLE1 was determined by quantitative PCR and
normalized to the level of alpha-tubulin gene expression (TUB1) at 10 min
without EV-086 or OA.OLE1 expression levels for 10g/ml OA and 10g/ml
EV-086 plus 10 g/ml OA were only analyzed at 120 min. *, P  0.01 by
one-way ANOVA with Dunnett’s post hoc test, compared to vehicle at 10 min.
Data are means standard errors (n	 3).
FIG 7 Ratio of saturated to unsaturated free fatty acids and PE fatty acyl chains of EV-086-treated S. cerevisiae cells. (a) Ratios of saturated to unsaturated free
fatty acids. Fatty acid nomenclature: 16:0, palmitic acid; 16:1, palmitoleic acid; 18:0, stearic acid; 18:1, oleic acid. (b) Ratios ofmajor PE fatty acyl chains. The ratios
between saturated and unsaturated fatty acyl chains of PE species with identical sum of carbon atoms is shown. PE nomenclature: sum of carbon atoms in acyl
chains:number of double bonds in acyl chains. P 0.001 (a) and P 0.0003 (b) by one-way ANOVAwith Dunnett’s post hoc test, compared to vehicle. Data are
means standard deviations (n	 3).
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acids suggests that EV-086 is metabolized similarly. We thus in-
vestigated whether exogenous EV-086 is incorporated into phos-
pholipids.
Haploid S. cerevisiaeBY4742was inoculated in SCmedium at a
density of 5 106 cells/ml. [14C]EV-086 or [14C]palmitic acid was
added at a concentration of 5 g/ml, and culture samples were
taken at 0, 30, 60, 120, and 240min. Lipidswere extracted from the
cell pellet and the cleared supernatant. The relative incorpora-
tion of [14C]EV-086 and [14C]palmitic acid into the cellular
lipid fraction was quantiﬁed by scintillation counting (Fig. 8a).
[14C]EV-086 accumulated in the lipid fraction in a time-de-
pendent manner, reaching 60% after 240 min. In comparison,
[14C]palmitic acid reached about 90% after 240 min. Separa-
tion of the lipid fractions by TLC indicated that both [14C]EV-
086 and [14C]palmitic acid were incorporated into phospho-
lipids, including phosphatidylcholines, phosphatidylinositols,
and phosphatidylethanolamines (Fig. 8b).
These results suggest that [14C]EV-086 is indeed recognized as
a fatty acid and incorporated into the phospholipid fraction. The
efﬁciency of uptake is 66%, compared to that of [14C]palmitic
acid. This difference likely reﬂects not only uptake speciﬁcity but
also the EV-086-mediated growth inhibition, which is not ob-
served for palmitic acid.
EV-086 has in vivo efﬁcacy in a guinea pig model of Tricho-
phyton skin dermatophytosis. EV-086 has proven broad-spec-
trum and potent antifungal activity in vitro. In order to investigate
its potential in vivo, EV-086 was tested in a guinea pig model of
Trichophyton skin dermatophytosis as previously described (27).
The activity of EV-086 against T. menagrophytes skin dermato-
phytosis in guinea pigs was assessed in ﬁve experimental groups:
untreated control, vehicle control, 0.1% EV-086, 1% EV-086, and
1% terbinaﬁne (Lamisil; Novartis) as the positive control. Square
areas of shaved and abraded skin on the backs of the animals were
infected withT.mentagrophytesATCC 24953 on day 1. Treatment
started on day 4 and lasted for 7 days, with daily applications of 0.2
ml of test product. On day 13, hair sample plugs were obtained
and cultured for mycological evaluation, and local changes of the
infected skin (redness, crusting, or lesions) were recorded for clin-
ical assessment (Fig. 9).
At a concentration of 1% in Captex 350, EV-086 demonstrated
a 92.5% mycological efﬁcacy (reduction of fungal positive hair)
and a 66% clinical efﬁcacy compared to the untreated control
(P 0.01).
DISCUSSION
Here, we report the identiﬁcation of the natural small molecule
EV-086 from the plant A. bellidifolium. EV-086 is a diyne-furan
fatty acid with potent and speciﬁc antifungal activity that targets
delta-9 fatty acid desaturation. To our knowledge, EV-086 is a
ﬁrst-in-class fungal delta-9 fatty acid inhibitor. The triazolidine-
thiones ECC145 and ECC188 have so far been the only other pub-
lished fungal delta-9 fatty acid desaturase inhibitors (45).
Chemical-genetic proﬁling of S. cerevisiae knockout mutants
has proven to be an effective strategy for the identiﬁcation of drug
targets (46). Here, we screened the S. cerevisiae ORF deletion li-
brary and identiﬁed 44 genes that confer hypersensitivity to EV-
086. Based on the identiﬁed genes and data in the literature, a
putative pathway controlling delta-9 fatty acid desaturation was
assembled as a possible target of EV-086.Whereas an involvement
of the GET complex in the localization of Mga2p is hypothetical
and needs further investigation, only recently has an involvement
of Ubx2p in the ERAD-dependent proteolysis of Mga2p been re-
ported (40). The roles of Ssm4p and Ubc7p in the ERAD process,
however, need further investigation. Transcript proﬁling suggests
that EV-086 targets delta-9 fatty acid desaturation not at the level
of Mga2p-dependent OLE1 transcription but rather posttran-
scriptionally at the biosynthetic level of delta-9 fatty acid desatu-
ration. The observed increase of OLE1 expression in response to
FIG 8 Uptake and incorporation of [14C]EV-086 into the lipid pool. (a) [14C]EV-086 and [14C]palmitate uptake, as the percentage of counts in the
cellular lipid fraction versus the sum of counts in the cellular lipid fraction and the cleared culture medium. Error bars show standard deviations (n	 3).
(b) TLC results for the phospholipid fraction. PC, phosphatidylcholines; PI, phosphatidylinositols; PS, phosphatidylserines; PE, phosphatidylethano-
lamines; PG, phosphatidylglycerols; PA, phosphatidic acids; NL, neutral lipids.
FIG 9 Efﬁcacy of EV-086 in a guinea pig model of T. mentagrophytes skin
dermatophytosis. The mycological and clinical efﬁcacies of the test products
are given as percentages in relation to the untreated control. *, P  0.01 by
one-way ANOVA with Dunnett’s post hoc test, compared to the untreated
control. Data are means standard errors (n 4).
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EV-086 indicated a compensatory effect of the cell for the delta-9
unsaturated fatty acid auxotrophy. A decrease of OLE1 transcrip-
tion would have been indicative of an inhibition of Mga2p or
other transcriptional regulators. Ole1p would therefore be the
most likely target of EV-086. However, puriﬁcation and charac-
terization ofOle1p in vitro has not been reported yet, and so far we
have been unable to purify Ole1p for an enzymatic assay.
We further identiﬁed TRP1, TRP5 and ARO2 from the aro-
matic amino acid biosynthetic pathway, as well as other genes
from amino acid biosynthetic pathways in the chemical-genetic
proﬁling. Tryptophan did not antagonize the inhibitory effect of
EV-086, as only a very slight decrease in sensitivity was observed
for S. cerevisiae in the presence of tryptophan (unpublished re-
sults). We speculate that EV-086 alters the membrane composi-
tion via inhibition of delta-9 fatty acid desaturation, thereby af-
fecting the function of various integral membrane proteins,
including tryptophan transporters (47). In agreement with this is
the ﬁnding that S. cerevisiae OLE1 mutants show a disintegration
of the nuclear envelope, which irreversibly damages the cell (48).
EV-086-dependent inhibition of delta-9 fatty acid desaturation
thus likely affects different membrane-associated processes lead-
ing to multiple physiological failures and subsequent cell death.
Furthermore, the heterodimeric transcription factors OAF1 and
PIP2 (49), which activate genes involved in beta-oxidation of fatty
acids, were identiﬁed in our screen. These mutants were more
susceptible to EV-086, whichmight indicate that beta-oxidation is
a mechanism for inactivation of EV-086 in yeast. Similarly, it has
been reported thatOaf1p andPip2p are involved in inactivation of
the toxic fatty acids octanoic acid and decanoic acid (50), and
OAF1 and PIP2 are upregulated in response to 6-nonadecynoic
acid (45).
The analysis of EV-086 analogues demonstrated that no
changes were tolerated at the carboxylic acid moiety and that the
conﬁguration of the C-9–C-10 carbon bond was critical for activ-
ity.Whereas a trans-9-decenoic conﬁguration was not active (EV-
086-trans), cis-9-decenoic acid (EV-086) or decanoic acid (EV-
086–9-saturated) conﬁgurations were active. The cis-9-decenoic
acid and decanoic acid conﬁgurations are conserved in common
fatty acids, including palmitic acid, palmitoleic acid, stearic acid,
oleic acid, or linoleic acid. Lipid analyses with labeled EV-086
suggested that EV-086 is integrated into phospholipids, likely as a
phospholipid fatty acyl chain. The impact of this incorporation on
the antifungal activity of EV-086 is so far unclear. However, it
might be that EV-086 is targeted to membranes as an EV-086–
phospholipid. Assuming that EV-086 inhibits Ole1p, EV-086–
phospholipids might colocalize with Ole1p in the ER membrane.
EV-086–phospholipids could then expose the EV-086 acyl chain
to the hydrophobic side of the phospholipid bilayer, and inhibi-
tion of Ole1p might take place at the transmembrane portion of
the protein.
Fatty acid biosynthesis as a target for antimicrobials has been
controversial (51). Although platensimycin has demonstrated an-
tibacterial activity in vivo by inhibiting FASII-dependent fatty acid
biosynthesis, another study suggested that bacterial pathogens
overcome drug-induced FASII pathway inhibition via comple-
mentation with serum fatty acids (52, 53). EV-086 has proven
efﬁcacy in a guinea pig model of T. mentagrophytes skin infection.
This validates delta-9 fatty acid desaturation as a target for this
indication and proves the efﬁcacy of the compound in vivo. T.
mentagrophytes therefore does not overcome EV-086-induced
delta-9 fatty acid desaturase inhibition via complementation with
skin unsaturated fatty acids. In contrast to the good efﬁcacy ob-
served in the guinea pigmodel ofT.mentagrophytes skin infection,
EV-086 was ineffective in rat and mouse models of systemic can-
didiasis (unpublished results). These ﬁndings could indicate that
C. albicans overcomes EV-086-induced delta-9 fatty acid desatu-
rase inhibition via complementationwith serumunsaturated fatty
acids. This in turn suggests thatC. albicans can rely on serum fatty
acids as a sole source of delta-9 unsaturated fatty acids and that C.
albicans delta-9 fatty acid desaturation is dispensable for virulence
in systemic infections. However, different studies have suggested
that OLE1-mediated delta-9 fatty acid desaturation is an essential
process for virulence (45, 54, 55). We therefore assume that the
inactivity of EV-086 observed in the systemic candidiasis studies is
related to the molecule and not the target. This, however, needs
further investigation.
In conclusion, EV-086 represents a novel class of antifungal
compounds that target delta-9 fatty acid desaturation, and it is a
novel lead antifungal compound with opportunities in human
fungal disease.
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